Patent application number | Description | Published |
20110090461 | APPARATUS FOR MEASUREMENT OF THE AXIAL LENGTH OF AN EYE - An apparatus for measuring the axial length of a human eye, the apparatus comprising a low coherence light source; a beam splitter; a fast displacement module for rapidly varying the path length within a reference arm of an interferometer; a laser directing a laser beam that is co-propagating with light from the low coherence light source into the displacement module. | 04-21-2011 |
20120013913 | FIBER-BASED INTERFEROMETRIC DEVICE FOR MEASURING AXIAL DIMENSIONS OF A HUMAN EYE - An apparatus for measuring a layered object comprising a low coherence light source, a coherent light source, and an interferometer including a reference arm and a measurement arm. The reference arm is comprised of a first section of polarization maintaining optical fiber engaged with a first fiber stretcher. The measurement arm is comprised of a second section of polarization maintaining optical fiber engaged with a second fiber stretcher. The first and second fiber stretchers are driven so as to alternatingly vary the lengths of the first section of polarization maintaining optical fiber and the second section of polarization maintaining optical fiber, thereby causing interference signals with the low coherence light when the length of the reference arm is equal to the length of the measurement arm including the distance from the second section of polarization maintaining optical fiber to any of the surfaces of the layers of the object. | 01-19-2012 |
20120287255 | PORTABLE FUNDUS CAMERA - A portable hand-held camera for imaging the fundus of an eye, the camera comprising a housing comprising an internal cavity terminating at a forward housing end, a forward lens, and a light source configured to direct light from locations distributed around the perimeter of the forward lens forwardly out of the housing end. In other embodiment, a portable hand-held camera for imaging the fundus of an eye includes optics configured to focus light reflected back from the fundus onto an image receptor, with the optics being capable of varying the field of view among differing portions of the fundus. Methods to ensure unique image identification and storage are described. | 11-15-2012 |
20140253907 | APPARATUS AND METHOD FOR EVALUATION OF OPTICAL ELEMENTS - An apparatus for measuring the optical performance characteristics and dimensions of an optical element comprising a low coherence interferometer and a Shack-Hartmann wavefront sensor comprising a light source, a plurality of lenslets, and a sensor array is disclosed. The low coherence interferometer is configured to direct a measurement beam along a central axis of the optical element, and to measure the thickness of the center of the optical element. The light source of the Shack-Hartmann wavefront sensor is configured to emit a waveform directed parallel to and surrounding the measurement beam of the interferometer, through the plurality of lenslets, and to the sensor array. A method for measuring the optical performance characteristics and dimensions of a lens using the apparatus is also disclosed. | 09-11-2014 |
20140267668 | PORTABLE FUNDUS CAMERA - A portable hand-held ocular fundus camera system for imaging the fundus of the eye is disclosed. The camera system is comprised of a camera housing, one or more groups of lens in an internal cavity of the housing, a front group of lenses at the front end of the internal cavity, a contact member to contact at least a portion of the cornea, a light source configured to direct light from locations inside the camera through an annulus near the periphery of the front lens group, so that the light enters the eye through an annulus at the periphery of the pupil of the eye during contact with the cornea. Light from the light source that is reflected off of the fundus that passes through the center portion of the pupil of the eye is imaged onto an imager configured to acquire a sequence of images while an actuator coupled to the imager continuously varies the location of the imager along the optical axis of the camera. | 09-18-2014 |
20150204756 | APPARATUS AND METHOD FOR EVALUATION OF OPTICAL ELEMENTS - An apparatus for measuring the optical performance characteristics and dimensions of an optical element comprising a low coherence interferometer and a Shack-Hartmann wavefront sensor comprising a light source, a plurality of lenslets, and a sensor array is disclosed. The low coherence interferometer is configured to direct a measurement beam along a central axis of the optical element, and to measure the thickness of the center of the optical element. The light source of the Shack-Hartmann wavefront sensor is configured to emit a waveform directed parallel to and surrounding the measurement beam of the interferometer, through the plurality of lenslets, and to the sensor array. A method for measuring the optical performance characteristics and dimensions of a lens using the apparatus is also disclosed. | 07-23-2015 |
Patent application number | Description | Published |
20080241166 | Ligands that bind a receptor - The invention relates to ligands, such as immunoglobulin single variable domains, that have binding specificity for a receptor. Preferably the receptor is a cell surface receptor and/or the ligand inhibits the activity of the receptor. | 10-02-2008 |
20090081233 | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 03-26-2009 |
20090258012 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders. | 10-15-2009 |
20100028354 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE - Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual. | 02-04-2010 |
20100081792 | Ligand - The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target. | 04-01-2010 |
20120201814 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE - Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual. | 08-09-2012 |
20130041136 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 02-14-2013 |
20130095109 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 04-18-2013 |
20130109846 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE | 05-02-2013 |
20130216538 | Compositions and Methods for Treating Inflammatory Disorders - The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders. | 08-22-2013 |
20140099707 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 04-10-2014 |
20150023976 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 01-22-2015 |
20150299321 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE - Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual. | 10-22-2015 |
20160075790 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 03-17-2016 |